Up to 40% of natural conceptions are spontaneously aborted, often before a woman knows she's pregnant. This is typically the body's way of rejecting embryos with severe genetic abnormalities. This natural process provides a powerful biological precedent for the practice of pre-implantation genetic screening.

Fears of regulatory hurdles for new manufacturing platforms may be overstated. Regulators, familiar with technologies like molecular farming for decades, prioritize the final product's purity, safety, and efficacy. The platform's novelty is secondary to robust scientific data proving the end product's quality.

Instead of mimicking slow, natural signaling (a process taking over a decade), Ovelle's approach directly activates gene regulatory factors that initiate meiosis. This method is significantly faster—starting the process in just 12 days—and offers more precise control over cell generation.

Many assume genetically modifying Mesenchymal Stem Cells (MSCs) is the main technical hurdle. The greater challenge is developing a robust, reproducible manufacturing process that delivers a functionally equivalent product every time, despite inherent variability from donors and process steps.

George Church bypasses the typical ethical debate, arguing germline editing faces three key business challenges: it doesn't apply to the 8 billion people already alive, clinical trials for late-onset diseases would take 80+ years, and it lacks a clear application not solvable by other means.

The manufacturing process fundamentally alters a cell therapy's properties. This creates a conundrum: starting with expensive, fully-automated systems is often unfeasible for early trials, but switching to automation later is risky. The high burden of proving the new process yields an equivalent product can stall late-stage development.

Varsavsky avoids polygenic screening (testing embryos for complex traits like IQ) because it's too speculative. He believes the probabilistic nature of the results and complex concepts like 'gene penetrance' are too difficult for the average patient to understand, making it an impractical, niche product for now.

Unlike autologous therapies where one batch treats one patient, a single batch of an allogeneic therapy can treat thousands. This scalability advantage creates a higher regulatory bar. Authorities demand exceptional robustness in the manufacturing process to ensure consistency and safety across a vast patient population, making the quality control challenge fundamentally different and more rigorous.

A crucial legal distinction in the US fuels investment in embryo editing. While creating babies from edited embryos is illegal, conducting research on them with private funds is not. This loophole allows startups to advance controversial science without immediate legal repercussions, attracting Silicon Valley capital.